A genetic variant (rs20417) of the PTGS2 gene, encoding for COX-2, has been associated with decreased COX-2 activity and a decreased risk of cardiovascular disease (CVD). However, this genetic association and the role of COX-2 in CVD remain controversial.
Introduction
Cyclooxygenase (COX) enzymes are responsible for converting arachidonic acid into prostaglandin (PG) H2, 1 which acts as a metabolic precursor of PGs, prostacyclin, and thromboxane. Three isoforms of the COX enzyme have been identified (COX-1, COX-2, and COX-3), but only the COX-1 and COX-2 isoforms are functional. The COX-1 enzyme is constitutively expressed in most tissues, including platelets, where it is involved in the formation of thromboxane A 2 through an intermediate. Low-dose aspirin decreases platelet activity by irreversibly acetylating COX-1 and inhibiting the production of platelet-derived thromboxane A 2 . 2 COX-2 is an inducible enzyme that is expressed by cells involved in inflammation (i.e. endothelial cells, monocytes, and macrophages). It is believed to have cardioprotective effects by facilitating the production of prostacyclin, which is a potent vasodilator and inhibits platelet activation and smooth muscle cell proliferation. 3 The role of COX-2 in atherothrombosis remains controversial. Some animal studies suggest that genetic inhibition of the COX-2 enzyme decreases the risk of atherosclerosis, 4 whereas others demonstrate an increased risk of thrombosis. 5 Most clinical studies have linked pharmacological inhibition by selective COX-2 inhibitors with an increased risk of cardiovascular events, 6 ,7 presumably because COX-2 inhibition leads to unopposed COX-1-dependent thromboxane production and subsequent platelet activation and vasoconstriction. 7 Additionally, higher doses of aspirin with shorter dosing intervals are required to inhibit the COX-2-dependent pathways since nucleated cells rapidly resynthesize this enzyme. 8 In contrast with these results, a genetic polymorphism (rs20417) in the promoter of the PTGS2 gene (COX-2) has been associated with lower COX-2 activity in atherosclerotic plaque and a decreased risk of myocardial infarction and stroke. 9 Furthermore, an interaction between aspirin use and carriage of the COX-2 polymorphism has been reported, whereby the genetic effect is stronger in aspirin users than non-users. 10, 11 However, previous studies mostly had small sample sizes, and only some 10 -14 but not all 15 -19 have replicated these findings. Thus confirmation and characterization of the genetic association between rs20417 and major adverse cardiovascular outcomes may provide greater insights into the biological role of COX-2 in cardiovascular disease (CVD), and may also improve risk stratification of CVD patients. Given the contradictory evidence on the role of COX-2 and CVD, we undertook to (i) test the association of the rs20417 polymorphism with CVD, (ii) examine whether the genetic association is modified by aspirin use, or the presence or absence of major CVD risk factors, and (iii) explore the functional mechanisms of the polymorphism by examining its impact on thromboxane and prostacyclin urine levels.
Methods

Study populations overview
The objective of this paper was to assess the effect of rs20417 carrier status with risk of CVD outcomes by combing the genetic effect estimates across six diverse patient populations. Events were classified according to definitions from each parent study. Our primary outcome was major adverse vascular events, defined, unless otherwise specified, as the composite of CVD death, non-fatal myocardial infarction, or non-fatal stroke.
Further details of the study population characteristics, genotyping, and imputation are described in Supplementary material online. In brief, ACTIVE-A was a randomized, double-blind, placebo-controlled trial comparing clopidogrel (75 mg/day) with placebo in patients with highrisk atrial fibrillation (AF). 20 CURE was a randomized, double-blind, placebo-controlled trial comparing clopidogrel (75 mg/day) with placebo in patients with acute coronary syndrome (ACS) without ST-segment elevation. 21 DREAM was a randomized, double-blind trial with a 2×2 factorial design that assigned participants at high risk for or who had diabetes to receive either ramipril (15 mg/day) vs. placebo or rosiglitazone (8 mg/day) vs. placebo. 22 The epiDREAM trial was an epidemiological arm of the DREAM trial and is comprised of participants who were either screened for eligibility to enter the DREAM clinical trial but were not eligible or who did not want to enter the trial but agreed to a long-term prospective follow-up. 23 ONTARGET was a randomized, double-blind, parallel trial comparing the effects of ramipril (10 mg/day), telmisartan (80 mg/day), and combination therapy in patients with vascular disease or high-risk diabetes patients. 24 RE-LY was a prospective, open-label, randomized trial that compared two fixed doses of dabigatran (110 or 150 mg twice daily) with open-label use of warfarin in patients with high-risk AF. 25 The WGHS study 26 is a subset of the Women's Health Study (WHS), 27 which consists of healthy female participants who were randomized either to an aspirin intervention arm (100 mg of aspirin every other day) or placebo. In addition, the INTERHEART study was a large, international, standardized case -control study consisting of non-fatal acute myocardial infarction cases and controls from 52 countries. 28 Finally, MARS was an open-label, two phase case-control study of individuals with CVD; however, for the purposes of this analysis, only healthy controls were considered. Urine was collected into preservative free tubes for the measurement of 11-dehydrothromboxane B 2 and urinary 2,3-dinor-6-keto PGF 1a using the standard method (Cayman Chemical, Ann Arbor, MI, USA).
Statistical analysis
Deviation from the Hardy-Weinberg equilibrium was tested in each ethnic group for each study (P . 0.05 for all). Owing to the limited number of individuals homozygous for the minor allele of rs20417, a dominant genetic model was used throughout, whereby individuals carrying either 1 or 2 minor alleles were pooled together, and thereafter referred as 'carriers' (unless otherwise specified). Logistic regression models were used for each individual study, with adjustment for age, sex, randomization status (when appropriate), and self-reported ethnicity. Results from each study were then combined using fixed-effect meta-analysis. Effect of rs20417 on outcomes was also assessed using Cox proportional hazard regression, without further adjustment. Association of rs20417 carrier status with urinary 11-dehydro thromboxane B 2 and 2,3-dinor-6-keto PGF 1 a concentrations was performed using a non-parametric Kruskal -Wallis test. The statistical significance threshold was set at 0.05 (two-sided) for all analyses. All analyses were performed using R Statistical Package.
Results
Characteristics of study populations
The baseline demographics of the prospective study populations (ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, RE-LY, and WGHS) are presented in Table 1 . The baseline demographics of the INTERHEART and MARS study populations are presented in Supplementary material online, Tables S1 and S2.
Association of the rs20417 polymorphism with major adverse cardiovascular events
Overall, 29.6% of participants were carriers of at least one rs20417 minor allele, similar to that of European Caucasian (CEU) individuals from HapMap (31.8%). Carrier status ranged from 23.2% in RE-LY to 34% in epiDREAM/DREAM. However, a proxy was used in ONTARGET and RE-LY, explaining the lower frequencies. Among the six prospective study populations (ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, RE-LY, and WGHS), rs20417 carrier status was significantly associated with a reduced risk of major cardiovascular outcomes [odds ratio (OR) ¼ 0.78, 95% confidence interval (CI) 0.70-0.87; P ¼ 1. (Figure 1 ). Heterogeneity across study populations was observed for major adverse cardiovascular events Association of cyclooxygenase-2 genetic variant (heterogeneity P ¼ 0.0017), as well as vascular death (heterogeneity P ¼ 0.025) and myocardial infarction (heterogeneity P ¼ 0.047). However, once CURE was removed from the pooled analyses, there was no longer evidence of heterogeneity (heterogeneity P . 0.05 for all). No interaction with randomized treatment was observed in each trial (ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, and RE-LY; P . 0.05 for all). As a sensitivity analysis, we also assessed rs20417 carrier status with risk of major CVD outcomes using an additive and unadjusted recessive model. Similar results were observed for the additive model (Supplementary material online, Figure S1 ), while associations were non-significant in the recessive model (data not shown).
Effect modification by aspirin use
Owing to the close biological relationship between COX-2 and aspirin, and previous reports of a genetic interaction with aspirin use, we tested rs20417 carrier status for association with cardiovascular events stratified by aspirin use. Aspirin use appeared to modify the relationship between rs20417 carrier status and risk of major cardiovascular events (heterogeneity P: 0.0041) ( Figure 2 ). Among participants using aspirin, carrier status was associated with a lower risk of CVD outcomes (OR: 0.74, 95% CI: 0.6420.84; P ¼ 1.20 × 10
25
), while this relationship was attenuated in aspirin non-users (OR: 0.87, 95% CI: 0.7221.06; P ¼ 0.16).We also observed significant heterogeneity among the pooled estimate of aspirin users, which points to differences between studies (heterogeneity P ¼ 0.0053).
As most patients on aspirin have established coronary artery disease (CAD), we also assessed the genetic association between rs20417 carrier statuses for adverse CVD events stratified by previous CAD (Figure 3) . Previous CAD was defined as established ACSs or angina. Previous CAD also appeared to modify the relationship between rs20417 carrier status and risk of cardiovascular outcomes (heterogeneity P: 0.015), where carriage of the rs20417 polymorphism had a stronger effect on risk of major adverse events among patients with previous CAD (OR: 0.69, 95% CI: 0.5820.81; P ¼ 1.10 × 10
) when compared with individuals without previous CAD (OR: 0.86, 95% CI: 0.74 21.00; P ¼ 0.06). No significant interaction with aspirin use was observed when restricting the analysis to individuals with previous CAD, although a trend towards a stronger effect was observed in aspirin users. However, only 186 rs20417 carriers with previous CAD were classified as non-aspirin users (Supplementary material online, Figure S2 ).
Genetic association in relation to other major cardiovascular disease risk factors
To evaluate the strength of the rs20417 carrier status association with CVD in relation to conventional risk factors, we utilized a multivariate analysis including rs20417 carrier status and other major CVD risk factors. Analyses were performed in ACTIVE-A and CURE because both studies were significantly associated with rs20417 carrier status in a univariate analyses and both had all participants on aspirin by design. Kaplan-Meier survival curves for ACTIVE-A and CURE are shown in Supplementary material online, Figure S3 , along with hazard ratios calculated using unadjusted Cox proportional hazard models. For ease of interpretation, individuals with two major rs20417 alleles were compared with individuals with one or more minor rs20417 alleles, such that carriage of two major rs20417 alleles is presented as a risk factor ( Table 2) . No conventional risk factors were consistently associated with a larger effect estimate than carriage of two major rs20417 alleles. In fact, carriage of two major rs20417 alleles had the largest effect size of all risk factors (excluding age) among participants in CURE (OR ¼ 1.90, 95% CI: 1.46-2.48; P ¼ 2.10 × 10
26
).
Effect modification by major cardiovascular disease risk factors
To explore whether the presence of specific CVD risk factors modified the association of rs20417 carrier status with cardiovascular outcomes, we performed subgroup analyses within the prospective populations (Supplementary material online, Figure S4 ). WGHS was excluded as there were no males and the prevalence of many risk factors (e.g. diabetes, advanced age) was low in this study of apparently healthy middle-aged women. None of the risk factors tested showed a significant interaction with carriage of the rs20417 minor allele (P . 0.05 for all). We also explored the association of rs20417 with myocardial infarction and its relation with major CVD risk factors in INTER-HEART. Overall, 32.3% of INTERHEART participants were carriers Figure 1 Association of rs20417 carrier status with major cardiovascular events in six prospective patient populations. Analyses were adjusted for age, sex, randomization status (when appropriate), and self-reported ethnicity. ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, RE-LY, and WGHS data were included in the meta-analysis. DREAM represents epiDREAM/DREAM. Hetero. P. represents heterogeneity P-value.
Association of cyclooxygenase-2 genetic variant of the rs20417 alternate allele (Supplementary material online, Table S1 ). There was no association between carrier status and nonfatal myocardial infarction when using a dominant genetic model (OR ¼ 0.93, 95% CI: 0.85-1.02; P ¼ 0.115) but a weak and consistent association was observed using an additive genetic model (OR ¼ 0.92, 95% CI: 0.85-0.99, P ¼ 0.02). There was a marginally significant interaction between apolipoprotein A1 (ApoA1) levels and carrier status (interaction P ¼ 0.017); whereby, carrier status was Figure 2 Analysis of association of rs20417 carrier status with major cardiovascular events stratified by aspirin use in six prospective patient populations. Analyses were adjusted for age, sex, randomization status (when appropriate), and self-reported ethnicity. ACTIVE-A, CURE, epiDREAM/ DREAM, ONTARGET, RE-LY, and WGHS data were included in the meta-analysis. DREAM represents epiDREAM/DREAM. Hetero. P. represents heterogeneity P-value. Figure 3 Analysis of association of rs20417 carrier status with major cardiovascular events stratified by previous coronary artery disease in six prospective patient populations. Analyses were adjusted for age, sex, randomization status (when appropriate), and self-reported ethnicity. ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, RE-LY, and WGHS data were included in the meta-analysis. DREAM represents epi-DREAM/DREAM. Hetero. P. represents heterogeneity P-value.
significantly associated with CVD among individuals with lower than median ApoA1 levels (OR ¼ 0.82, 95% CI: 0.73-0.93, P ¼ 0.002) but not among those with greater than median ApoA1 levels (OR ¼ 1.05, 95% CI 0.93-1.20, P ¼ 0.42) (Supplementary material online, Figure S5 ). None of the other modifiable risk factors or clinical characteristics showed a significant interaction with carrier status (P . 0.05 for all). We also assessed whether the rs20417 polymorphism was associated with CVD risk factors using a model adjusted for age, sex, and ethnicity. None of the risk factors was significantly associated with carrier status (P . 0.05 for all) (Supplementary material online, Table S3 ).
Association of rs20417 with urinary metabolites of thromboxane and prostacyclin
Finally, we tested whether rs20417 carrier status was associated with COX-1 and COX-2 derived urinary 11-dehydrothromboxane B 2 and urinary 2,3-dinor-6-keto PGF 1a in 117 healthy European participants (not taking aspirin or other COX inhibitors). Minor allele carriers had decreased 11-dehydrothromboxane B 2 urine concentration (P ¼ 0.01), with median values of 97.0 ng/mmol creatinine and 126.0 ng/mmol creatinine in carriers (n ¼ 32) and non-carriers (n ¼ 85), respectively. In addition, minor allele carriers also had decreased urinary 2,3-dinor-6-keto PGF 1a concentration (P ¼ 0.01), with median values of 3335.8 pg/mg creatinine and 4790.4 pg/mg creatinine in carriers (n ¼ 32) and non-carriers (n ¼ 85), respectively (Supplementary material online, Figure S6 ).
Discussion
We found that the COX-2 (PTGS2) genetic variant rs20417 is associated with a decreased risk of major cardiovascular events (OR ¼ 0.78, 95% CI: 0.70-0.87, P ¼ 1.20 × 10 25 ), with consistent effects for cardiovascular death, myocardial infarction, and stroke. We also observed significant interactions with aspirin use (Heterogeneity P: 0.0041) and previous CAD (Heterogeneity P: 0.015). Indeed, in ACTIVE-A and CURE, the magnitude of CVD risk associated with carriage of two major rs20417 alleles was similar to that of traditional risk factors, such as sex, diabetes, smoking status, high blood pressure, and obesity. Similar to previous reports, we observed an interaction between the non-selective COX inhibitor aspirin and rs20417 carrier status. 10, 11 While the possibility of a biological interaction is compelling, this association may also be confounded since aspirin users are also more likely to represent those with established CVD and thereby reflect a stronger genetic effect in higher risk populations 29 rather than an interaction with aspirin use. Indeed, the clinical benefit of aspirin itself parallels the baseline risk of study populations, with a 12% proportional reduction in CVD events in primary prevention population, 30 19% in secondary prevention, 30 and 23% relative reduction in death in the acute ACS setting. 31 Consistent with this hypothesis, previous CAD appeared to enhance the association between rs20417 carrier status and risk of CVD outcomes (Heterogeneity P: 0.015). Similarly, we found no association between rs20417 and CVD risk in WGHS, a population in which the originally reported aspirin benefit was modest, 27 and we observed a strong association in ACS without ST-segment elevation patients enrolled in the CURE trial. This strong association may have also been driven by the fact that CURE participants were assigned a standard dose aspirin (75-325 mg daily) when compared with the healthy female participants in WGHS who were randomly allocated to either treatment with low-dose aspirin (100 mg every other day) or placebo. Thus, the net clinical benefit of aspirin could vary according to carrier status. For instance, the difference in major adverse cardiovascular event rate between rs20417 carriers and non-carriers (6.0 vs. 11.1%) was larger than the absolute risk of major and minor bleeds (2.8 and 2.1%) in CURE participants randomized to aspirin alone.
In agreement with the previous work showing that the rs20417 minor allele is linked to decreased COX-2 expression, 9, 19 we demonstrated that minor allele carriers had lower levels of both urinary 11-dehydrothromboxane B 2 and urinary 2,3-dinor-6-keto PGF 1a excretion. We posit that tissue-specific effects of the genetic variant could explain the apparent discrepancy between genetic and pharmacological inhibition of COX-2 activity with respect to cardiovascular risk. This may also explain the apparent heterogeneity among studies since participants with more advanced stages of CVD are likely to have complex, macrophage-rich plaques. Indeed, the largest genetic effect was observed among the secondary prevention patients in CURE, which had a dominant effect in our meta-analysis. Thus, CURE participants are expected to have more advanced atherosclerosis and may be more susceptible to the COX-2 inhibiting effect of rs20417. However, further research is required to fully assess the functional role of COX-2 in primary and secondary prevention patients. Several factors likely contributed to the previously inconsistent reports of an association between rs20417 and risk of CVD. 15 -19 For instance, the sample size among several studies exploring the rs20417 association ranged from 220 15 to 4994, 11 which indicates that some of these studies may not have had enough statistical power to detect a genetic effect. Also, case-control studies may have underestimated the reported association between rs20417 minor allele carriers and CVD outcomes since these studies are more likely to include COX-2 carriers who experienced non-fatal vascular events as opposed to those who experienced vascular death. Indeed, inclusion of a large number of individuals from prospective studies strengthens our meta-analysis. Finally, it is possible that the genetic effect varies according to study population and aspirin exposure such that heterogeneous estimates reflect true genetic risks. Nonetheless, we did not observe any significant interactions among the clinical risk factors tested in INTERHEART with the exception of ApoA1 (interaction P-value: 0.017). High-density lipoproteins and ApoA1 have been both shown to up-regulate COX-2 expression and induce prostacyclin synthesis in endothelial cells. 28 High-density lipoproteins and ApoA1 have been both shown to up-regulate COX-2 expression and induce prostacyclin synthesis in endothelial cells. 32 -34 However, the observed interaction was of modest statistical significance and should be considered exploratory since it would not withstand adjustment for multiple testing. A few limitations of our study warrant discussion. First, tissuespecific gene expression would ideally be needed to delineate the effects of rs20417 on COX-2 gene expression in relevant tissues such as endothelial cells, atherosclerosis plaques, and macrophages. Second, rs20417 was not directly genotyped in ONTARGET or in RE-LY and could not be imputed such that a proxy was used. 35 However, use of a proxy should bias our results towards the null without invalidating our conclusions. Third, while the genetic effect was consistent across ethnic groups in both the epiDREAM/ DREAM and INTERHEART patient populations, our study populations were predominantly European and further studies will be needed to confirm in other ethnic groups. Finally, although our results suggest an interaction between ApoA1 levels and carriers of the rs20417 genotype with CVD, this was an exploratory analysis and further work is needed.
In summary, we confirmed the protective effect of the minor allele of the COX-2 (PTGS2) SNP, providing a genetic link between COX-2 activity and cardiovascular risk. In particular, our data suggest that decreased COX-2 activity is not universally deleterious in humans with respect to risk of adverse CVD outcomes, and taken together with observations in human atherosclerosis plaques and model systems implies that inhibition of COX-2 in macrophages could be beneficial. Additionally, the biologically compelling interaction between rs20417 carrier status and aspirin use suggests that widely prescribed non-selective COX inhibitors may be more beneficial among rs20417 carriers. Our results also highlight the complex genetic epidemiology of CVD and argue that genetic determinants may have different effect sizes according to study population characteristics, such as aspirin use or presence of vascular disease. Further research will be needed to fully delineate the clinical, epidemiological, and pathophysiological implications of the observed genetic association.
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